Drug profile · INN
dinutuximab
UNITUXIN
dinutuximab (UNITUXIN) is a disialoganglioside gd2 binding agent. Associated with United Therapeutics Europe Ltd. Route of administration: intravenous. Current US regulatory status: approved.
Drug details — dinutuximab
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- INTRAVENOUS
- Patents
- 20
- Programs
- 4
- Data quality
- 0.89
Quick answer
dinutuximab (UNITUXIN) is a disialoganglioside gd2 binding agent. Associated with United Therapeutics Europe Ltd. Route of administration: intravenous. Current US regulatory status: approved.
Key facts
Mechanism of action
Disialoganglioside GD2 binding agent
Primary target: Disialoganglioside GD2
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | withdrawn | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 12383500
Nanoliposome compositions and methods of using the same
granted -
US 12383618
Expression vector delivery system and use thereof for inducing an immune response
granted -
US 12383554
Compositions and methods to protect mammalian tissue against cold and other metabolic stresses
granted -
US 12384820
Griffithsin mutants
granted -
US 12350274
Nucleotide analogs
granted -
US 12343432
Encapsulated probiotic
granted -
US 12336974
Methods and compositions for preventing and treating auditory dysfunctions
granted -
US 12325688
Gingerenone A prodrugs as sensotherapeutics and methods of use
granted -
US 12298315
Systems and methods to identify and treat subjects at risk for obstetrical complications
granted -
US 12286657
Methods and compositions
granted -
US 12281060
Remodilins for airway remodeling and organ fibrosis
granted -
US 12281336
Chikungunya virus (CHIKV) virus-like particles (VLPS) comprising the C, E1, and E2 structural proteins
granted -
US 12275758
Prefusion RSV F proteins and their use
granted -
US 12269803
Krüppel-like factor 15 (KLF15) small molecule agonists in kidney disease
granted -
US 12268749
Cell-penetrating peptides
granted -
US 12239654
Compounds and methods for treating neurological and cardiovascular conditions
granted -
US 12226423
Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25HC3S) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide
granted -
US 12215164
Immunotoxins with albumin binding domain
granted -
US 12214031
Mannheimia haemolytica vector
granted -
US 12210017
Peptides representing epitopes from filoviruses
granted
Frequently asked questions
What is dinutuximab?
dinutuximab (UNITUXIN) is a disialoganglioside gd2 binding agent. Associated with United Therapeutics Europe Ltd. Route of administration: intravenous. Current US regulatory status: approved.
What is the brand name for dinutuximab?
UNITUXIN is a marketed brand name for dinutuximab. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of dinutuximab?
dinutuximab has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.